Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 12:49:29 2024-04-26 am EDT			5-day change	1st Jan Change
4,988 ^JPY	+4.66%		+7.59%	+28.82%

Apr. 25	Scholz pledges further support for the pharmaceutical industry	DP
Apr. 25	Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	MT

Daiichi Sankyo Company, Limited Forecasts Dividend for the Second Quarter of Fiscal Year Ending March 31, 2022

July 30, 2021 at 12:00 am EDT

Daiichi Sankyo Company, Limited forecasted dividend for the second quarter of fiscal year ending March 31, 2022. For the quarter, the company forecasted dividend of JPY 13.50 per share against JPY 40.50 per share paid a year ago.

Latest news about Daiichi Sankyo Co., Ltd.

Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	Apr. 25	MT
AstraZeneca upbeat as cancer drugs underpin sales growth	Apr. 25	AN
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.	Apr. 25	CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.	Apr. 24	CI
Middle East Tensions Dent Asian Stock Markets	Apr. 19	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	Apr. 08	MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	Apr. 08	MT
AstraZeneca: US approval extended for Enhertu	Apr. 08	CF
AstraZeneca hails neurological data for Ultomiris, Soliris	Apr. 08	AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	Apr. 08	MT
Astra hails neurology data; CVS flags cyberattack	Apr. 08	AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	Apr. 08	AN
AstraZeneca Wins US Approval for Solid Tumor Treatment	Apr. 07	MT
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	Apr. 05	CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	Apr. 05	RE
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03	MT
Merck: 1st patient in raludotatug study	Apr. 03	CF
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI
AstraZeneca, Daiichi make US progress with licence approvals	Apr. 03	AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction	Apr. 02	MT
AstraZeneca, Daiichi Sankyo Say US FDA Accepts Their Biologics License Application for Breast Cancer Treatment	Apr. 02	MT
AstraZeneca and Daiichi make US progress with latest licence approvals	Apr. 02	AN
AstraZeneca, Daiichi Sankyo's Jointly Developed Breast Cancer Treatment Accepted for US Regulatory Review	Apr. 02	MT

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4,766 JPY

Average target price

5,620 JPY

Spread / Average Target

+17.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+28.82%	58.76B
NOVO NORDISK A/S	+24.17%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.45%	233B
NOVARTIS AG	+6.04%	201B
ROCHE HOLDING AG	-10.51%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Forecasts Dividend for the Second Quarter of Fiscal Year Ending March 31, 2022

EPS Revisions